Hemosol B0

Hemosol B0 is an intravenous electrolyte solution that combines calcium, magnesium, sodium, chloride, lactate, and hydrogen carbonate in a balanced formulation. It is supplied as a sterile liquid for infusion and is marketed in the European Union. The product is intended to support fluid and electrolyte balance in clinical settings where patients require intravenous replacement of essential minerals and buffering capacity.

Hemosol B0 is used in hospital and clinical environments to address specific electrolyte and fluid needs. It is typically considered when patients have conditions that affect mineral balance or acid‑base status.

- Replacement of calcium, magnesium, sodium, and chloride in patients with deficits. - Management of metabolic acidosis through lactate conversion to bicarbonate. - Support during major surgery or trauma when large fluid shifts occur. - Adjunct therapy for patients receiving parenteral nutrition. - Treatment of hypovolemia when isotonic fluid replacement is required.

Side effects of Hemosol B0 may vary in frequency and severity. Monitoring is recommended during administration.

Common: - Mild hypercalcemia presenting as nausea or fatigue. - Transient hypermagnesemia causing flushing or warmth. - Slight elevation of serum sodium leading to mild thirst. - Temporary increase in urinary output. - Mild metabolic alkalosis reflected in blood gas analysis.

Serious: - Severe hypercalcemia with cardiac arrhythmia. - Marked hypermagnesemia resulting in respiratory depression. - Rapid shifts in serum electrolytes causing seizures. - Overcorrection of acidosis leading to metabolic alkalosis complications.

When using Hemosol B0, clinicians should observe several safety considerations to minimize risk. Patient assessment and laboratory monitoring are essential.

- Verify baseline electrolyte levels and acid‑base status before infusion. - Adjust infusion rate in patients with renal impairment to avoid accumulation. - Use caution in individuals with congestive heart failure or fluid overload risk. - Monitor cardiac rhythm in patients with known arrhythmias. - Avoid rapid bolus administration; prefer controlled infusion. - Ensure compatibility with other intravenous solutions before mixing.

Hemosol B0 can interact with other medications or solutions, influencing electrolyte balance or infusion compatibility. Awareness of these interactions helps maintain patient safety.

Avoid: - Co‑administration with calcium channel blockers that may exacerbate hypercalcemia. - Simultaneous infusion with high‑potassium solutions that could cause precipitation. - Use with certain blood products that may alter calcium levels.

Use with caution: - Concurrent diuretics that affect sodium and magnesium excretion. - ACE inhibitors or ARBs in patients prone to hyperkalemia. - Antacids containing magnesium or aluminum. - Medications that influence renal handling of electrolytes, such as aminoglycosides.